AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25179634
Drug: sSOAIC (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sSOAIC (standard selective ophthalmic artery infusion chemotherapy)
Trial: 25179634
Drug: bSOAIC (balloon-assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bSOAIC (balloon-assisted selective ophthalmic artery infusion chemotherapy)
Trial: 25179634
Drug: Verapamil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil infusion into the OA and internal carotid artery
Trial: 25180155
Drug: Ruxolitinib (JAK1/2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib (JAK1/2 inhibitor)
Trial: 25180584
Drug: High-quantity lipid-based
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-quantity lipid-based nutrient supplements (HQ-LNS) with cash (€38/month)
Trial: 25180584
Drug: Medium-quantity lipid-based
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-quantity lipid-based nutrient supplements (MQ-LNS) with cash (€38/month)
Trial: 25180584
Drug: High-quantity lipid-based
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-quantity lipid-based nutrient supplements (HQ-LNS) only
Trial: 25181387
Drug: Surgery and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery and chemotherapy for ovarian cancer
Trial: 25182067
Drug: Public health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Public health nurse-administered program in Prince Edward Island
Trial: 25182067
Drug: Physician-administered program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician-administered program in Nova Scotia
Trial: 25185097
Drug: TH-302 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TH-302 plus doxorubicin induction treatment
Trial: 25185097
Drug: TH-302 maintenance
RxNorm normalized name: cenobamate
DrugBank: Cenobamate (DB06119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: TH-302 maintenance therapy
Trial: 25185712
Drug: Cyclophosphamide at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide at 120 mg/kg plus cyclosporine and prophylaxis
Trial: 25185712
Drug: Cyclophosphamide at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide at 120 mg/kg
Trial: 25186780
Drug: Non-surgical periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical periodontal therapy with adjunctive systemic antibiotics
Trial: 25190651
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of AOSLO and OCT
Trial: 25191915
Drug: Low-dose buprenorphine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose buprenorphine (0.2-1.6 mg/d, mean dose 0.4 mg/d, mean maximum dose 0.7 mg/d)
Trial: 25191939
Drug: C1-esterase inhibitor
RxNorm normalized name: HUMAN C1-ESTERASE INHIBITOR
DrugBank: Human C1-esterase inhibitor (DB06404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C1-esterase inhibitor (C1-inh) administered intravenously at a dose 30-fold greater than that approved for hereditary angioedema (HAE).
Trial: 25191939
Drug: C1-esterase inhibitor
RxNorm normalized name: HUMAN C1-ESTERASE INHIBITOR
DrugBank: Human C1-esterase inhibitor (DB06404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C1-esterase inhibitor (C1-inh) at a dose of 2000 units in humans.
Trial: 25191939
Drug: C1-esterase inhibitor
RxNorm normalized name: HUMAN C1-ESTERASE INHIBITOR
DrugBank: Human C1-esterase inhibitor (DB06404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C1-esterase inhibitor (C1-inh) combined with polysulfated macromolecules (heparin and dextran sulfate).
Trial: 25192745
Drug: Simeprevir (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simeprevir (150 mg once daily) with pegylated interferon alfa-2a/ribavirin (peg-IFN/RBV) for 12 weeks.
Trial: 25193617
Drug: Delayed-release mesalamine
RxNorm normalized name: mesalamine Delayed Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-release mesalamine tablets formulated with MMX technology, 8 weeks of treatment for active mild-to-moderate UC.
Trial: 25193617
Drug: Delayed-release mesalamine
RxNorm normalized name: mesalamine Delayed Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-release mesalamine tablets formulated with MMX technology, 12 months of maintenance treatment for quiescent UC.
Trial: 25197009
Drug: Deferasirox (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferasirox (once daily)
Trial: 25198661
Drug: Endostar (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endostar (15 mg/day) combined with gemcitabine (1,000 mg/m(2) on days 1 and 8) and cisplatin (80 mg/m(2) on day 1) for a maximum of four cycles.
Trial: 25199919
Drug: Striatal dopamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Striatal dopamine D2-like receptor binding potential (D2BP) measured using positron emission tomography with [(18)F]fallypride
Trial: 26704626
Drug: Empagliflozin 25
RxNorm normalized name: empagliflozin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 25 mg single dose
Trial: 25200052
Drug: Concurrent valve
RxNorm normalized name: VALVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent valve procedures
Trial: 25200593
Drug: Postoperative experience
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative experience as described by patients and caregivers through daily diary entries assessing functional autonomy, postoperative pain, and caregiver burden.
Trial: 25200593
Drug: Daily diary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily diary responses from patients and caregivers regarding their postoperative experience.
Trial: 25201125
Drug: DuraSeal polyethylene
RxNorm normalized name: polyethylenes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DuraSeal polyethylene glycol (PEG) gel used as a spacer during low-dose rate brachytherapy.
Trial: 29905488
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) treatment for 8 weeks
Trial: 25202139
Drug: Once-weekly bortezomib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly bortezomib 1.6 mg/m²
Trial: 25202139
Drug: Twice-weekly bortezomib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly bortezomib 1.3 mg/m²
Trial: 25203178
Drug: Pulsed-field gel
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed-field gel electrophoresis (PFGE) analysis
Trial: 25203869
Drug: β-D-glucan test
RxNorm normalized name: yeast, beta-D-glucan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-D-glucan test (cut-off 80 pg/ml)
Trial: 25203869
Drug: β-D-glucan test
RxNorm normalized name: yeast, beta-D-glucan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-D-glucan test (cut-off 200 pg/ml)
Trial: 25208108
Drug: Individualized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized treatment approaches for abdominal pain in IBD patients; specific interventions not detailed.
Trial: 25209003
Drug: Multi-omic molecular
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multi-omic molecular profiling (MMP) informed selection of approved cancer treatments
Trial: 25209396
Drug: Intravesical sphingomyelin
RxNorm normalized name: Valrubicin Intravesical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical sphingomyelin liposomes (4 weekly instillations)
Trial: 25209657
Drug: Video capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video capsule endoscopy (VCE)
Trial: 25210104
Drug: Benznidazole (BNZ)
RxNorm normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benznidazole (BNZ) administered for 30 days, median dose 5.65 mg/kg/day twice daily
Trial: 25210104
Drug: Benznidazole (BNZ)
RxNorm normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benznidazole (BNZ) administered for 30 days
Trial: 25210883
Drug: Standard 4-hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 4-hour glucagon stimulation test (GST) with a peak GH cutoff of 3 ng/mL
Trial: 25210883
Drug: Standard 4-hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 4-hour glucagon stimulation test (GST) with a peak GH cutoff of 1 ng/mL
Trial: 25213183
Drug: Vorinostat maintenance
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vorinostat maintenance therapy (oral agent) for 21 consecutive days starting day + 60 after autologous transplant, followed by a week off for up to 11 cycles.
Trial: 25213183
Drug: Vorinostat maintenance
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vorinostat maintenance therapy
Trial: 25217112
Drug: BIL >1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIL >1 mg/dl (>17.1 µmol/l) and CHE ≤ 5,900 U/l
Trial: 25217734
Drug: Low 25(OH)D
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low 25(OH)D levels (Group 1a, ≤5 ng/mL)
Trial: 25217734
Drug: Low 25(OH)D
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low 25(OH)D levels (Group 1b, 5-15 ng/mL)
Trial: 25217734
Drug: Normal 25(OH)D
RxNorm normalized name: 1α,25(OH)2D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal 25(OH)D levels (Group 2, >15 ng/mL)
Trial: 25219292
Drug: Idursulfase beta
RxNorm normalized name: idursulfase beta
DrugBank: Idursulfase beta (DB16190)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Idursulfase beta (0.5mg/kg/week) administered intravenously for 52 weeks
Trial: 25220020
Drug: Oral delta-9-tetrahydrocannabinol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral delta-9-tetrahydrocannabinol (THC) treatments
Trial: 25220528
Drug: Pulse pressure
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse pressure variation (PPV)-guided fluid therapy
Trial: 25220574
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous ascorbic acid (AA) at doses of 5, 30, and 60 g
Trial: 25221606
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 2,000 I.U. daily for 12 weeks
Trial: 25222119
Drug: Zidovudine (ZDV)
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine (ZDV) prophylaxis for PMTCT or triple antiretroviral treatment in pregnancy
Trial: 25223394
Drug: Adalimumab (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (40 mg) administered subcutaneously every other week
Trial: 25223394
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg loading dose of adalimumab
Trial: 25224842
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose tolerance testing (OGTT) with 300 ml of glucose-containing fluid
Trial: 25224842
Drug: Mixed-meal tolerance
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed-meal tolerance testing (MMTT) with 237 ml of fat/protein/carbohydrate-containing fluid
Trial: 25225206
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with ACE2 and Ang-(1-7)
Trial: 25225420
Drug: Single-agent carfilzomib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent carfilzomib (56 mg/m2)
Trial: 25225420
Drug: Carfilzomib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carfilzomib plus low-dose dexamethasone (45 or 56 mg/m2)
Trial: 25225420
Drug: Single-agent carfilzomib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent carfilzomib (70 mg/m2)
Trial: 25225420
Drug: Single-agent carfilzomib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent carfilzomib (20 to 56 mg/m2)
Trial: 25225420
Drug: Carfilzomib (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carfilzomib (various doses)
Trial: 25225437
Drug: Cabozantinib 100
RxNorm normalized name: cabozantinib 100 MG Daily Dose Carton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 100 mg
Trial: 25225676
Drug: DNA vaccines
RxNorm normalized name: Toxoplasma gondii DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNA vaccines (4 mg administered intramuscularly by Biojector at weeks 0, 4, and 8, with a homologous boost at or after week 32)
Trial: 25225676
Drug: DNA vaccines
RxNorm normalized name: Toxoplasma gondii DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNA vaccines (4 mg administered intramuscularly by Biojector)
Trial: 25225962
Drug: NaviAid G-EYE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaviAid G-EYE balloon-colonoscope
Trial: 25226293
Drug: Exogenous kisspeptin
RxNorm normalized name: Kisspeptin
DrugBank: Kisspeptin (DB19112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exogenous kisspeptin (0.24 nmol/kg) administered intravenously
Trial: 25226293
Drug: GnRH (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH (75 ng/kg) administered intravenously
Trial: 25226407
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g ethanol
Trial: 25227179
Drug: High saturated
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High saturated fat diet + 3.45 g/d of docosahexaenoic acid (DHA) for 8 weeks
Trial: 25230939
Drug: Tdap5 (Adacel)
RxNorm normalized name: Adacel
DrugBank: Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (DB10991)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tdap5 (Adacel) vaccine administered to 10-year-olds
Trial: 25232260
Drug: Anti-mycotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-mycotic therapy based on the developed algorithm
Trial: 25234930
Drug: Cetuximab (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetuximab (400 mg/m2 at first infusion and 250 mg/m2 subsequently) combined with cisplatin (80 mg/m2, triweekly) and capecitabine (2,000 mg/m2, triweekly for 2 weeks)
Trial: 25236503
Drug: 3 Ms
RxNorm normalized name: DRESSING,OPTIFOAM NON-ADHES 3X3 MSC1133F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 Ms (Medication, Meter, and Meals) intervention
Trial: 25236916
Drug: IgPro20 (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgPro20 (subcutaneous immunoglobulin)
Trial: 25239228
Drug: Sorafenib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 400 mg twice daily after HSCT for 12 cycles (28 days each).
Trial: 25239610
Drug: MK-2206 60
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-2206 60 mg QOD
Trial: 25239610
Drug: MK-2206 200
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-2206 200 mg QW
Trial: 25240453
Drug: On-treatment LDL-C
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On-treatment LDL-C levels <70 mg/dl
Trial: 25240453
Drug: On-treatment LDL-C
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On-treatment LDL-C levels ≥70 mg/dl
Trial: 25241933
Drug: Δ Sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Δ Sequential Organ Failure Assessment (SOFA) score measured at ICU admission and after 48 hours
Trial: 25242374
Drug: Eribulin mesylate
RxNorm normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eribulin mesylate (1.4 mg/m(2)) with trastuzumab (4 mg/kg loading dose followed by 2 mg/kg weekly doses)
Trial: 25242374
Drug: Eribulin mesylate
RxNorm normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eribulin mesylate (1.4 mg/m(2)) with trastuzumab (8 mg/kg loading dose followed by 6 mg/kg tri-weekly doses)
Trial: 25242417
Drug: Intermittent androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent androgen deprivation (IAD) with 9 months of leuprolide and flutamide followed by off-treatment interval.
Trial: 25245327
Drug: High-dose interleukin-2
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose interleukin-2 (HD-IL-2) at a dose of 18 MIU/m2/day by continuous IV infusion for 72 hours, repeated every 3 weeks for up to 4 cycles and then every 4 weeks for a further 2 cycles.
Trial: 25245327
Drug: Booster radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster radiotherapy (XRT) at 6-12 Gy administered in three daily doses on days -3 to -1 before the first and third cycle of IL-2.
Trial: 25245327
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of HD-IL-2 and XRT.
Trial: 25245624
Drug: Adalimumab 160
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab 160 mg at the start, 80 mg 2 weeks later, followed by 40 mg every other week for 52 weeks (with some patients increasing to 80 mg every other week)
Trial: 25245629
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with azathioprine
Trial: 25247300
Drug: Meningococcal vaccines
RxNorm normalized name: Meningococcal vaccines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal vaccines targeting fHbp
Trial: 25248945
Drug: Oral artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral artesunate (ARS) 100, 150, or 200 mg OD
Trial: 25248945
Drug: Oral artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral artesunate (ARS)
Trial: 25250858
Drug: RO4929097 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO4929097 (20 mg daily, 3 consecutive days per week)
Trial: 25253045
Drug: Oral panobinostat
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral panobinostat (30 mg single dose for core phase, then thrice-weekly for extension phase)
Trial: 25254044
Drug: NRT (30 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRT (30 mg of cocoa polyphenols, 80 mg of soy isoflavones, and 2 gr of myo-inositol)
Trial: 25254563
Drug: Intraperitoneal catumaxomab
RxNorm normalized name: catumaxomab
DrugBank: Catumaxomab (DB06607)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal catumaxomab (10, 20, 50, and 150 μg within 10 days)
Trial: 25260365
Drug: Estradiol (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol (6 mg/day for 3 months)
Trial: 25260365
Drug: Low-dose estradiol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose estradiol treatment
Trial: 25260365
Drug: Overall effectiveness
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall effectiveness of treatment
Trial: 25260842
Drug: tasisulam combined
RxNorm normalized name: Tasisulam
DrugBank: Tasisulam (DB11941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tasisulam combined with 1,000 mg/m² gemcitabine HCl (days 1 and 15)
Trial: 25260842
Drug: tasisulam combined
RxNorm normalized name: Tasisulam
DrugBank: Tasisulam (DB11941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tasisulam combined with 60 mg/m² docetaxel
Trial: 25260842
Drug: tasisulam combined
RxNorm normalized name: Tasisulam
DrugBank: Tasisulam (DB11941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tasisulam combined with 200 mg/m²/day temozolomide
Trial: 25260842
Drug: tasisulam combined
RxNorm normalized name: Tasisulam
DrugBank: Tasisulam (DB11941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tasisulam combined with 75 mg/m² cisplatin
Trial: 25260842
Drug: tasisulam combined
RxNorm normalized name: Tasisulam
DrugBank: Tasisulam (DB11941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tasisulam combined with 150 mg/day erlotinib
Trial: 25261424
Drug: Raltegravir 400
RxNorm normalized name: raltegravir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir 400 mg twice daily with rifampicin thrice weekly
Trial: 25261424
Drug: Raltegravir 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir 800 mg twice daily with rifampicin thrice weekly
Trial: 25261716
Drug: Homemade bilayer
RxNorm normalized name: Welmedix Homecare Pro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homemade bilayer adhesive patch (AOS)
Trial: 25261839
Drug: Sofosbuvir and
RxNorm normalized name: sofosbuvir and ledipasvir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir and ribavirin (400 mg) treatment for up to 48 weeks before liver transplantation
Trial: 25262042
Drug: PST plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PST plus antidepressant medications
Trial: 25262042
Drug: Antidepressant medications
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant medications alone
Trial: 25262042
Drug: Overall depression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall depression treatment
Trial: 25264305
Drug: Crizotinib at
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Crizotinib at the standard oral dose of 250 mg twice daily